Teon Therapeutics is a private biopharma company developing a novel pipeline of GPCR-targeting small molecules for use in oncology. GPCRs are a proven drug target, accounting for >30% of all FDA approved drugs, and have emerged as a high potential target in oncology, particularly adenosine pathways in the tumor microenvironment. Teon has assembled top GPCR biologists and chemists with decades of industry experience, and was seeded by Northern Light Ventures in 2018.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
TT-702 (A2BR antagonist)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):